Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of TPOXX When Administered Orally for 28 Days in Adult Subjects

NCT04971109 is registered in ClinicalTrials.gov with SIGA Technologies as lead sponsor.

NCT NCT04971109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04971109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of TPOXX When Administered Orally for 28 Days in Adult Subjects
Lead sponsor
SIGA Technologies
Phase
Phase 3
Overall status
Completed
Start date
March 29, 2022
Completion date
May 12, 2023
Enrollment
467 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

smallpox